You just read:

AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma

News provided by

AbbVie Inc.

Sep 26, 2016, 07:00 ET